Results 301 to 310 of about 146,874 (392)

The use of granulocyte colony-stimulating factors in the management of breast cancer patients. [PDF]

Front Oncol
Bałata A, Szombara E, Nowecki ZI, Pogoda K.   +3 more
europepmc   +1 more source

Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions

MedComm, Volume 6, Issue 10, October 2025.
PROTACs are reshaping drug discovery through targeted protein degradation. Clinical programs now extend to prostate, breast, lung, hematologic, and solid tumors, with key targets including AR, ER, BTK, STAT3, Bcl‐xL, BRD9, Kras, and so on. These degraders overcome resistance, broaden therapeutic scope, and provide solutions for “undruggable” proteins ...
Gang Fan, Shilin Chen, Qingping Zhang, Na Yu, Ziyang Shen, Zhaoji Liu, Weiming Guo, Zhihan Tang, Jing Yang, Miao Liu   +9 more
wiley   +1 more source

Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study. [PDF]

Breast
Zietse M, Hu J, van Staveren ER, Spierings LEAMM, Jager A, Koch BCP, Mathijssen RHJ, van Leeuwen RWF, Thielen FW.   +8 more
europepmc   +1 more source

Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies. [PDF]

Lancet Reg Health Eur
Jourdain H, Di Meglio A, Mansouri I, Desplas D, Zureik M, Haddy N.   +5 more
europepmc   +1 more source

The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances

MedComm, Volume 6, Issue 10, October 2025.
Immunotherapy, serving as a crucial breakthrough of precision medicine in the field of cancer treatment, among which immune checkpoint inhibitors (ICIs) have witnessed the most extensive application. This review systematically investigates the challenges, advancements, and future directions of ICIs in tumor treatment.
Hengyi Chen, Hongling Yang, Lu Guo, Qingxiang Sun   +3 more
wiley   +1 more source

Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases. [PDF]

Int J Clin Oncol
Anders C, Neuberger E, Schwartz NRM, Bartley K, Wang S, Liu Y, Pittner BT, Kaufman PA, Meisel J.   +8 more
europepmc   +1 more source

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Annals of Oncology, 2014
S. Loi, S. Loi, S. Michiels, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M. Piccart, S. Loibl, C. Denkert, M. Smyth, H. Joensuu, C. Sotiriou   +17 more
semanticscholar   +1 more source

Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives

MedComm, Volume 6, Issue 10, October 2025.
This review summarizes strategies to optimize lipid nanoparticles (LNPs) for improved targeting, endosomal escape, and safety. It highlights mRNA design, alternative delivery systems, and recent therapeutic advances across infectious diseases, cancer, and drug applications.
Xiaochi Li, Junli Li, Jiazheng Wei, Weixin Du, Cheng Su, Xiaobin Shen, Aihua Zhao, Miao Xu   +7 more
wiley   +1 more source

Cardiac function surveillance practices and outcomes in patients with HER2-positive breast cancer treated with trastuzumab: a retrospective cohort study across a safety-net and tertiary care setting. [PDF]

Cardiooncology
Huang L, Manthena P, Su M, Chandra A, Sadeghi N.   +4 more
europepmc   +1 more source

An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo

Protein Science, Volume 34, Issue 10, October 2025.
Abstract Erythropoietin (EPO) initiates EPO receptor (EPOR) signaling in hematopoietic cells by binding to an asymmetric EPOR dimer through two different sites. We engineered dimeric diabody‐Fc (Db‐Fc) fusion proteins that appeared to act as potent agonists of human EPOR in cell proliferation assays. However, detailed analysis of their oligomeric forms
Jarrett J. Adams, Levi L. Blazer, Jacky Chung, Minoo Karimi, Taylor Davidson, Heather A. Bruce, Alexander U. Singer, Ning Yang, Lia Cardarelli, Isabelle Pot, Luigi Colombo, Lily Jun‐shen Huang, Yue Ma, Stephen W. Michnick, Orson W. Moe, Sachdev S. Sidhu   +15 more
wiley   +1 more source